Global Parenteral PrEP Market Growth 2026-2032
Description
The global Parenteral PrEP market size is predicted to grow from US$ 285 million in 2025 to US$ 787 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.
Parenteral PrEP refers to HIV pre-exposure prophylaxis delivered via non-enteral routes—most commonly long-acting intramuscular injections, and in broader usage also implants or other sustained-release parenteral platforms—designed to maintain protective drug concentrations over extended intervals before potential HIV exposure occurs. In practice today, the term largely maps to long-acting injectable PrEP (e.g., long-acting cabotegravir), with the wider pipeline including implants and long-acting biologics. The central problem it addresses is not the pharmacologic efficacy of PrEP per se (daily oral PrEP is highly effective when taken as prescribed), but the implementation gap: adherence burden, missed doses, access continuity, and privacy/stigma concerns that can reduce real-world effectiveness; by shifting protection from “remember a pill every day” to “receive a dose every 1–2 months (or longer),” parenteral PrEP aims to deliver more consistent coverage and simplify prevention for people who struggle with, dislike, or cannot safely sustain oral regimens.In 2025, the global production capacity of parenteral PrEP reached 150,000 doses, while total sales amounted to 109,800 doses. The average selling price was USD 2,650 per dose, and the gross margin of manufacturers ranged between 60% and 70%.
The current parenteral PrEP market is in a transitional phase where clinical effectiveness is well established, but health systems and delivery models are still adapting to long-acting prevention. Acceptance among clinicians, public health authorities, and at-risk communities has grown steadily, particularly in populations where daily oral PrEP has faced adherence or continuity challenges. At the same time, the market shows a clear dual-track pattern: in higher-income settings, parenteral PrEP is typically integrated into structured medical care with an emphasis on monitoring and long-term management, while in resource-limited or high-incidence settings it is often embedded within public health programs aimed at reducing population-level transmission and stigma. As a result, uptake is shaped less by lack of interest than by variation in system readiness to support repeat dosing, follow-up, and logistics.
Looking ahead, the market is expected to evolve from reliance on a single dominant modality toward a landscape where multiple long-acting technologies coexist. Injectable approaches are likely to remain central in the near term, but innovation is increasingly focused on extending dosing intervals, offering alternative delivery formats, and pairing biomedical prevention with digital follow-up and community-based services. Parenteral PrEP is gradually being repositioned from a simple substitute for oral regimens to a flexible prevention option that can be tailored to different risk profiles, life circumstances, and care settings. Over time, competitive differentiation is likely to hinge on user experience and service integration, including convenience, discretion, and reduced long-term burden on both patients and providers.
The main drivers of this market include the persistent gap between proven efficacy and real-world adherence, growing policy emphasis on sustainable HIV prevention strategies, and ongoing advances in drug formulation and delivery science. At the same time, several constraints continue to shape adoption, such as dependence on healthcare infrastructure, the need for trained personnel and regular follow-up, social stigma and uneven awareness, and concerns around long-term safety or reversibility among certain users. The interaction of these forces suggests that growth in parenteral PrEP will be evolutionary rather than abrupt, unfolding alongside broader changes in health policy, service delivery, and social acceptance rather than through rapid, uniform expansion.
LP Information, Inc. (LPI) ' newest research report, the “Parenteral PrEP Industry Forecast” looks at past sales and reviews total world Parenteral PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Parenteral PrEP sales for 2026 through 2032. With Parenteral PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parenteral PrEP industry.
This Insight Report provides a comprehensive analysis of the global Parenteral PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parenteral PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Parenteral PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parenteral PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parenteral PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Parenteral PrEP market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Cabotegravir
Lenacapavir
Other
Segmentation by Dosing Interval:
Short-interval Injections
Monthly Injections
Quarterly Injections
Segmentation by Drug Properties:
Original Drug
Generic Drug
Segmentation by Application:
Subcutaneous Use
Intramuscular Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
ViiV Healthcare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Parenteral PrEP market?
What factors are driving Parenteral PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Parenteral PrEP market opportunities vary by end market size?
How does Parenteral PrEP break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Parenteral PrEP refers to HIV pre-exposure prophylaxis delivered via non-enteral routes—most commonly long-acting intramuscular injections, and in broader usage also implants or other sustained-release parenteral platforms—designed to maintain protective drug concentrations over extended intervals before potential HIV exposure occurs. In practice today, the term largely maps to long-acting injectable PrEP (e.g., long-acting cabotegravir), with the wider pipeline including implants and long-acting biologics. The central problem it addresses is not the pharmacologic efficacy of PrEP per se (daily oral PrEP is highly effective when taken as prescribed), but the implementation gap: adherence burden, missed doses, access continuity, and privacy/stigma concerns that can reduce real-world effectiveness; by shifting protection from “remember a pill every day” to “receive a dose every 1–2 months (or longer),” parenteral PrEP aims to deliver more consistent coverage and simplify prevention for people who struggle with, dislike, or cannot safely sustain oral regimens.In 2025, the global production capacity of parenteral PrEP reached 150,000 doses, while total sales amounted to 109,800 doses. The average selling price was USD 2,650 per dose, and the gross margin of manufacturers ranged between 60% and 70%.
The current parenteral PrEP market is in a transitional phase where clinical effectiveness is well established, but health systems and delivery models are still adapting to long-acting prevention. Acceptance among clinicians, public health authorities, and at-risk communities has grown steadily, particularly in populations where daily oral PrEP has faced adherence or continuity challenges. At the same time, the market shows a clear dual-track pattern: in higher-income settings, parenteral PrEP is typically integrated into structured medical care with an emphasis on monitoring and long-term management, while in resource-limited or high-incidence settings it is often embedded within public health programs aimed at reducing population-level transmission and stigma. As a result, uptake is shaped less by lack of interest than by variation in system readiness to support repeat dosing, follow-up, and logistics.
Looking ahead, the market is expected to evolve from reliance on a single dominant modality toward a landscape where multiple long-acting technologies coexist. Injectable approaches are likely to remain central in the near term, but innovation is increasingly focused on extending dosing intervals, offering alternative delivery formats, and pairing biomedical prevention with digital follow-up and community-based services. Parenteral PrEP is gradually being repositioned from a simple substitute for oral regimens to a flexible prevention option that can be tailored to different risk profiles, life circumstances, and care settings. Over time, competitive differentiation is likely to hinge on user experience and service integration, including convenience, discretion, and reduced long-term burden on both patients and providers.
The main drivers of this market include the persistent gap between proven efficacy and real-world adherence, growing policy emphasis on sustainable HIV prevention strategies, and ongoing advances in drug formulation and delivery science. At the same time, several constraints continue to shape adoption, such as dependence on healthcare infrastructure, the need for trained personnel and regular follow-up, social stigma and uneven awareness, and concerns around long-term safety or reversibility among certain users. The interaction of these forces suggests that growth in parenteral PrEP will be evolutionary rather than abrupt, unfolding alongside broader changes in health policy, service delivery, and social acceptance rather than through rapid, uniform expansion.
LP Information, Inc. (LPI) ' newest research report, the “Parenteral PrEP Industry Forecast” looks at past sales and reviews total world Parenteral PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Parenteral PrEP sales for 2026 through 2032. With Parenteral PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parenteral PrEP industry.
This Insight Report provides a comprehensive analysis of the global Parenteral PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parenteral PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Parenteral PrEP market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parenteral PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parenteral PrEP.
This report presents a comprehensive overview, market shares, and growth opportunities of Parenteral PrEP market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Cabotegravir
Lenacapavir
Other
Segmentation by Dosing Interval:
Short-interval Injections
Monthly Injections
Quarterly Injections
Segmentation by Drug Properties:
Original Drug
Generic Drug
Segmentation by Application:
Subcutaneous Use
Intramuscular Use
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Gilead Sciences
ViiV Healthcare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Parenteral PrEP market?
What factors are driving Parenteral PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Parenteral PrEP market opportunities vary by end market size?
How does Parenteral PrEP break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
85 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Parenteral PrEP by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Parenteral PrEP by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
